Trial · NCT05287126
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Participants Achieving Clinical Remission as Assessed by Modified Mayo Score (MMS) at Week 52 | Week 52 | |
| Secondary | Plasma Concentration of Etrasimod at 4 Hours Post-dose (C4h) | 4 hours (± 15 minutes) post-dose | |
| Secondary | Plasma Steady State Trough Concentration (Ctrough,ss) of Etrasimod | pre-dose and 4 hours (±15 minutes) post-dose at Day 1; at trough concentrations (approximately 24 hours after the dose taken the day before the study visit) at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52 | |
| Secondary | Proportion of Participants Achieving Clinical Remission as Assessed by MMS at Week 12 | Week 12 | |
| Secondary | Proportion of Participants Achieving Endoscopic Improvement at Week 12 | Week 12 | |
| Secondary | Proportion of Participants Achieving Endoscopic Improvement at Week 52 | Week 52 | |
| Secondary | Proportion of Participants Achieving Symptomatic Remission at Week 12 | Week 12 | |
| Secondary | Proportion of Participants Achieving Symptomatic Remission at Week 52 | Week 52 | |
| Secondary | Proportion of Participants with Clinical Remission at Week 12 Who Had Not been Receiving Corticosteroids for ≥ 2 weeks Prior to Week 12 | Week 12 | |
| Secondary | Proportion of Participants with Clinical Remission at Week 52 Who Had Not been Receiving Corticosteroids for ≥ 12 weeks Prior to Week 52 | Week 52 | |
| Secondary | Proportion of Participants Achieving Clinical Response at Week 12 | Week 12 | |
| Secondary | Proportion of Participants Achieving Clinical Response at Week 52 | Week 52 | |
| Secondary | Proportion of Participants Achieving Clinical Remission by Pediatric Ulcerative Colitis Activity Index (PUCAI) at Week 12 | Week 12 | |
| Secondary | Proportion of Participants Achieving Clinical Remission as Assessed by PUCAI at Week 52 | Week 52 | |
| Secondary | Proportion of Participants Achieving a Clinical Response as Assessed by PUCAI at Week 12 | Week 12 | |
| Secondary | Proportion of Participants Achieving a Clinical Response as Assessed by PUCAI at Week 52 | Week 52 | |
| Secondary | Number and Severity of Adverse Events | Up to Week 52 | Safety will be assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05287126/registered